BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer

Liefaard, M. C.; van der Voort, A.; van Ramshorst, M. S.; Sanders, J.; Vonk, S.; Horlings, H. M.; Siesling, S.; de Munck, L.; van Leeuwen, A. E.; Kleijn, M.; Mittempergher, L.; Kuilman, M. M.; Glas, A. M.; Wesseling, J.; Lips, E. H.; Sonke, G. S.

doi:10.1186/s13058-023-01664-x

Breast Cancer Research

Article metrics
Last updated: Sat, 18 May 2024 15:56:03 Z

BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer

Access & Citations

1709

Article Accesses
0

Web of Science
2

CrossRef

Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.

ISSN: 1465-542X

Contact us

Submission enquiries: journalsubmissions@springernature.com